Evolution of therapies for chronic myelogenous leukemia

Fabio P.S. Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed for CML, and it led to high rates of complete cytogenetic responses and improved survival for patients with this disease. However, approximately 35% of patients in chronic phase treated with imatinib will develop resistance or intolerance to this drug. The recognition of the problem of imatinib failure led to the design of second-generation TKI (dasatinib, nilotinib, and bosutinib). These drugs are highly active in the scenario of imatinib resistance or intolerance. More recently, both nilotinib and dasatinib were approved for frontline use in patients with chronic phase CML. Ponatinib represents the last generation of TKI, and this drug has been developed with the aim of targeting a specific BCR-ABL1 mutation (T315I), which arises in the setting of prolonged TKI therapy and leads to resistance to all commercially available TKI. Parallel to the development of specific drugs for treating CML, major advances were made in the field of disease monitoring and standardization of response criteria. In this review, we summarize how therapy with TKI for CML has evolved during the last decade.

Original languageEnglish (US)
Pages (from-to)465-476
Number of pages12
JournalCancer Journal
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pharmaceutical Preparations
Therapeutics
Leukemia, Myeloid, Chronic Phase
Cytogenetics
Mutation
Survival
Imatinib Mesylate
Proteins

Keywords

  • BCR-ABL1
  • bosutinib
  • Chronic myelogenous leukemia
  • dasatinib
  • imatinib
  • nilotinib
  • ponatinib
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evolution of therapies for chronic myelogenous leukemia. / Santos, Fabio P.S.; Kantarjian, Hagop; Quintás-Cardama, Alfonso; Cortes, Jorge.

In: Cancer Journal, Vol. 17, No. 6, 01.11.2011, p. 465-476.

Research output: Contribution to journalReview article

Santos, FPS, Kantarjian, H, Quintás-Cardama, A & Cortes, J 2011, 'Evolution of therapies for chronic myelogenous leukemia', Cancer Journal, vol. 17, no. 6, pp. 465-476. https://doi.org/10.1097/PPO.0b013e31823dec8d
Santos, Fabio P.S. ; Kantarjian, Hagop ; Quintás-Cardama, Alfonso ; Cortes, Jorge. / Evolution of therapies for chronic myelogenous leukemia. In: Cancer Journal. 2011 ; Vol. 17, No. 6. pp. 465-476.
@article{08659821fab3452f9dba3786c6a4e1b3,
title = "Evolution of therapies for chronic myelogenous leukemia",
abstract = "The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed for CML, and it led to high rates of complete cytogenetic responses and improved survival for patients with this disease. However, approximately 35{\%} of patients in chronic phase treated with imatinib will develop resistance or intolerance to this drug. The recognition of the problem of imatinib failure led to the design of second-generation TKI (dasatinib, nilotinib, and bosutinib). These drugs are highly active in the scenario of imatinib resistance or intolerance. More recently, both nilotinib and dasatinib were approved for frontline use in patients with chronic phase CML. Ponatinib represents the last generation of TKI, and this drug has been developed with the aim of targeting a specific BCR-ABL1 mutation (T315I), which arises in the setting of prolonged TKI therapy and leads to resistance to all commercially available TKI. Parallel to the development of specific drugs for treating CML, major advances were made in the field of disease monitoring and standardization of response criteria. In this review, we summarize how therapy with TKI for CML has evolved during the last decade.",
keywords = "BCR-ABL1, bosutinib, Chronic myelogenous leukemia, dasatinib, imatinib, nilotinib, ponatinib, tyrosine kinase inhibitors",
author = "Santos, {Fabio P.S.} and Hagop Kantarjian and Alfonso Quint{\'a}s-Cardama and Jorge Cortes",
year = "2011",
month = "11",
day = "1",
doi = "10.1097/PPO.0b013e31823dec8d",
language = "English (US)",
volume = "17",
pages = "465--476",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Evolution of therapies for chronic myelogenous leukemia

AU - Santos, Fabio P.S.

AU - Kantarjian, Hagop

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed for CML, and it led to high rates of complete cytogenetic responses and improved survival for patients with this disease. However, approximately 35% of patients in chronic phase treated with imatinib will develop resistance or intolerance to this drug. The recognition of the problem of imatinib failure led to the design of second-generation TKI (dasatinib, nilotinib, and bosutinib). These drugs are highly active in the scenario of imatinib resistance or intolerance. More recently, both nilotinib and dasatinib were approved for frontline use in patients with chronic phase CML. Ponatinib represents the last generation of TKI, and this drug has been developed with the aim of targeting a specific BCR-ABL1 mutation (T315I), which arises in the setting of prolonged TKI therapy and leads to resistance to all commercially available TKI. Parallel to the development of specific drugs for treating CML, major advances were made in the field of disease monitoring and standardization of response criteria. In this review, we summarize how therapy with TKI for CML has evolved during the last decade.

AB - The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed for CML, and it led to high rates of complete cytogenetic responses and improved survival for patients with this disease. However, approximately 35% of patients in chronic phase treated with imatinib will develop resistance or intolerance to this drug. The recognition of the problem of imatinib failure led to the design of second-generation TKI (dasatinib, nilotinib, and bosutinib). These drugs are highly active in the scenario of imatinib resistance or intolerance. More recently, both nilotinib and dasatinib were approved for frontline use in patients with chronic phase CML. Ponatinib represents the last generation of TKI, and this drug has been developed with the aim of targeting a specific BCR-ABL1 mutation (T315I), which arises in the setting of prolonged TKI therapy and leads to resistance to all commercially available TKI. Parallel to the development of specific drugs for treating CML, major advances were made in the field of disease monitoring and standardization of response criteria. In this review, we summarize how therapy with TKI for CML has evolved during the last decade.

KW - BCR-ABL1

KW - bosutinib

KW - Chronic myelogenous leukemia

KW - dasatinib

KW - imatinib

KW - nilotinib

KW - ponatinib

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=83755188045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755188045&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31823dec8d

DO - 10.1097/PPO.0b013e31823dec8d

M3 - Review article

C2 - 22157290

AN - SCOPUS:83755188045

VL - 17

SP - 465

EP - 476

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 6

ER -